EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Nabriva Therapeutics's Enterprise Value is $-1.64 Mil.
Nabriva Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was $-53.71 Mil. Therefore, Nabriva Therapeutics's EV-to-EBIT for today is 0.03.
The historical rank and industry rank for Nabriva Therapeutics's EV-to-EBIT or its related term are showing as below:
NBRVF'
s EV-to-EBIT Range Over the Past 10 Years
Min: -1.58 Med: -0.08 Max: 0.33
Current: 0.03
During the past 10 years, the highest EV-to-EBIT of Nabriva Therapeutics was 0.33. The lowest was -1.58. And the median was -0.08.
NBRVF's EV-to-EBIT is ranked better than 97.3% of 444
companies
in the Biotechnology industry
Industry Median: 8.325
vs NBRVF: 0.03
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Nabriva Therapeutics's Enterprise Value for the quarter that ended in Jun. 2023 was $3.24 Mil.
Nabriva Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was $-53.71 Mil. Nabriva Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -1,659.41%.
Nabriva Therapeutics EV-to-EBIT Historical Data
The historical data trend for Nabriva Therapeutics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Nabriva Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nabriva Therapeutics EV-to-EBIT Distribution
For the Biotechnology industry and Healthcare sector, Nabriva Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Nabriva Therapeutics's EV-to-EBIT falls into.
Nabriva Therapeutics EV-to-EBIT Calculation
Nabriva Therapeutics's EV-to-EBIT for today is calculated as:
Nabriva Therapeutics's current Enterprise Value is $-1.64 Mil.
Nabriva Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-53.71 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Nabriva Therapeutics's Enterprise Value for the quarter that ended in Jun. 2023 was $3.24 Mil.
Nabriva Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-53.71 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nabriva Therapeutics EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Nabriva Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Nabriva Therapeutics (Nabriva Therapeutics) Business Description
Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NBRVF has been successfully added to your 